The effect of insulin glargine and fish oil supplements on atherosclerosis progression

August 27, 2012

A sub-study of the Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial, designed to investigate the effect of insulin glargine and omega-3 fatty acids on atherosclerosis progression, has found that, compared to standard care, only insulin glargine (a long-acting insulin) had a "modest" statistically non-significant reducing effect on the primary outcome of rate of change in maximum carotid intima media thickness (CIMT) at 12 carotid sites.

However, while glargine did significantly reduce the secondary outcomes of the study (the annualised rates of change in maximum CIMT for the common carotid artery and for the common carotid plus bifurcation sites), there was no differences in either the primary or secondary outcomes between the omega-3 polyunsaturated and placebo groups.

"Our study demonstrates that in high-risk people with established cardiovascular disease or with plus type 2 diabetes or pre-diabetes, insulin glargine modestly retards the progression of atherosclerosis," said first investigator Professor Eva Lonn, Professor of Medicine and Population Health Research Scientist at McMaster University, Hamilton, Ontario, Canada.

As background to the trial, known as the Glucose Reduction and Atherosclerosis Continuing Evaluation Study (GRACE) study, Professor Lonn explained that the effects of treatment with insulin titrated to normalise fasting and with omega-3 polyunsaturated fatty acid supplements () on atherosclerosis progression in people with type 2 diabetes or pre-diabetes are unknown.

The GRACE study assessed the effects of insulin glargine and omega-3 by performing yearly high-resolution carotid ultrasound examinations for five years and detailed of CIMT. Patients were recruited from 32 centers in seven countries. At baseline patients' mean age was 63 years, over 50% had a history of prior heart attack, stroke or revascularisation, 80% had hypertension, 60% abnormal cholesterol and 10% were current smokers. About 90% had type 2 diabetes and 10% had pre-diabetes.

Most patients were receiving several therapies aimed at reducing their risk for atherosclerosis and its complications. Use of these drugs increased over the duration of the study, so that at study end 52% were on statins, 75% on ACE inhibitors or ARBs, 55% on beta-blockers and 70% on aspirin. Patients received open label insulin glargine targeting normal glucose levels or standard glycemic care, and double-blind therapy with a 1 gram per day supplement of or placebo. Median follow-up was five years.

Insulin glargine significantly lowered fasting plasma glucose, glycated hemoglobin and triglyceride levels and provided overall "excellent" glycemic control, said Professor Lonn, while omega-3 fatty acid supplements had no significant effect on glycemia or on lipid levels. Both interventions were safe.

Compared with the standard glycemic care, insulin glargine reduced the primary CIMT outcome, but the difference was not statistically significant (difference = 0.0030 ±0.0021 mm/year; p=0.145) and significantly reduced the secondary outcomes (difference = 0.0033 ±0.0017 mm/year; p=0.049 and 0.0045 ±0.0021 mm/year; p=0.032). There was no beneficial effect of omega-3 polyunsaturated fatty acid supplements on either outcome.

"These findings support the cardiovascular safety of this intervention," said Professor Lonn, "and suggest that longer term treatment with insulin glargine might prevent cardiovascular events. In the parent ORIGIN trial had a neutral effect on cardiovascular events over 6.2 years. Whether longer-term therapy may result in clinical event reduction remains currently unproven."

"The neutral effect of omega-3 polyunsaturated fatty acid supplements on atherosclerotic vascular disease is also concordant with the neutral effect on clinical cardiovascular effects in the parent ORIGIN trial. Some, but not all, previous studies reported beneficial effects of omega-3 polyunsaturated fatty acid supplements in cardiovascular event prevention and several large ongoing trials are still evaluating this question. Our study does not address the current recommendations to consume more fish, which may have health benefits not conferred by fish oil supplements."

Explore further: Study debunks belief insulin puts people with diabetes at risk of heart disease

Related Stories

Study debunks belief insulin puts people with diabetes at risk of heart disease

June 11, 2012
Researchers at McMaster University have discovered that long-term insulin use does not harm people with diabetes or pre-diabetes or put them at risk of heart attacks, strokes or cancer.

Fish oil won't save diabetics' hearts, research suggests

June 11, 2012
(HealthDay) -- People with type 2 diabetes who take omega-3 fatty acid supplements are neither helping nor harming their heart, a new study finds.

Omega-3 supplements no help against repeat heart trouble: review

April 9, 2012
(HealthDay) -- Taking omega-3 fatty acid supplements won't protect against repeat heart attacks, strokes or other cardiovascular problems, a new analysis indicates.

Vitamin B and omega-3 supplementation and cancer: new data

February 17, 2012
Researchers from the Nutritional Epidemiology Joint Research Unit have just published a study showing that, in men with a previous history of cardiovascular pathologies, supplementation with B vitamins and omega-3 polyunsaturated ...

Omega-3 fatty acids not associated with beneficial effects in multiple sclerosis: study

April 23, 2012
Omega-3 fatty acid supplements were not associated with beneficial effects on disease activity in patients with relapsing-remitting multiple sclerosis, according to a report of a randomized controlled trial published Online ...

Recommended for you

Could this protein protect people against coronary artery disease?

November 17, 2017
The buildup of plaque in the heart's arteries is an unfortunate part of aging. But by studying the genetic makeup of people who maintain clear arteries into old age, researchers led by UNC's Jonathan Schisler, PhD, have identified ...

New model estimates odds of events that trigger sudden cardiac death

November 16, 2017
A new computational model of heart tissue allows researchers to estimate the probability of rare heartbeat irregularities that can cause sudden cardiac death. The model, developed by Mark Walker and colleagues from Johns ...

Popular e-cigarette liquid flavorings may change, damage heart muscle cells

November 16, 2017
Chemicals used to make some popular e-cigarette liquid flavorings—including cinnamon, clove, citrus and floral—may cause changes or damage to heart muscle cells, new research indicates.

Possible use for botulinum toxin to treat atrial fibrillation

November 16, 2017
From temporarily softening wrinkles to easing migraines, botulinum toxin has become a versatile medical remedy because of its ability to block nerve signals that can become bothersome or risky.

Proteome of the human heart mapped for the first time

November 15, 2017
A healthy heart beats about two billion times during a lifetime, thanks to the interplay of more than 10,000 proteins. Researchers from the Max Planck Institute of Biochemistry (MPIB) and the German Heart Centre at the Technical ...

First transcatheter implant for diastolic heart failure successful

November 15, 2017
Results presented today at the American Heart Association Scientific Sessions and published in Circulation show that a new device designed to treat diastolic heart failure is safe and effective. The first patient in the randomized, ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.